Alternative donor allogeneic hematopoietic cell transplantation for hemoglobinopathies

Seminars in Hematology

Volumn 53, Issue 2, 2016, Pages 120-128

  Alfraih, Feras ^a   Aljurf, Mahmoud ^b   Fitzhugh, Courtney D ^c   Kassim, Adetola A ^c  

^a KING FAISAL SPECIALIST HOSPITAL AND RESEARCH CENTER   (Saudi Arabia)

^b NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^c VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Allogeneic hematopoietic stem cell transplantation; Alternative donor; Hemoglobinopathies; Sickle cell disease; Thalassemia

Indexed keywords

ALEMTUZUMAB; AZATHIOPRINE; BUSULFAN; CYCLOPHOSPHAMIDE; FILGRASTIM; FLUDARABINE; HYDROXYUREA; RAPAMYCIN; THIOTEPA; THYMOCYTE ANTIBODY; TREOSULFAN;

ACUTE GRAFT VERSUS HOST DISEASE; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ALTERNATIVE DONOR ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; CHIMERA; CHRONIC GRAFT VERSUS HOST DISEASE; DONOR; DRUG EFFICACY; ENGRAFTMENT; GRAFT FAILURE; HEMOGLOBINOPATHY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MORBIDITY; MORTALITY; MYELOABLATIVE CONDITIONING; NONMYELOABLATIVE CONDITIONING; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PRIORITY JOURNAL; PROGNOSIS; REDUCED INTENSITY CONDITIONING; RELATED HAPLOIDENTICAL DONOR; REVIEW; SICKLE CELL ANEMIA; THALASSEMIA; TREATMENT INDICATION; TREATMENT OUTCOME; UMBILICAL CORD BLOOD; UNRELATED DONORS; WHOLE BODY RADIATION; ADVERSE EFFECTS; ALLOTRANSPLANTATION; GRAFT VS HOST DISEASE; HAPLOIDY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMOGLOBINOPATHIES; HISTOCOMPATIBILITY TEST;

GRAFT VS HOST DISEASE; HAPLOIDY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMOGLOBINOPATHIES; HISTOCOMPATIBILITY TESTING; HUMANS; TRANSPLANTATION, HOMOLOGOUS;

EID: 84961186768     PISSN: 00371963     EISSN: 15328686     Source Type: Journal    
DOI: 10.1053/j.seminhematol.2016.01.001     Document Type: Review

References (70)

1. Giardine B., Borg J., Viennas E., et al. Updates of the HbVar database of human hemoglobin variants and thalassemia mutations. Nucleic Acids Res 2014, 42:D1063-D1069.
2. Weatherall D.J. The inherited diseases of hemoglobin are an emerging global health burden. Blood 2010, 115(22):4331-4336.
3. Wayne A.S., Schoenike S.E., Pegelow C.H. Financial analysis of chronic transfusion for stroke prevention in sickle cell disease. Blood 2000, 96(7):2369-2372.
4. Neufeld E.J. Oral chelators deferasirox and deferiprone for transfusional iron overload in thalassemia major: new data, new questions. Blood 2006, 107(9):3436-3441.
5. Taher A.T., Musallam K.M., El-Beshlawy A., et al. Age-related complications in treatment-naive patients with thalassaemia intermedia. Br J Haematol 2010, 150(4):486-489.
6. Leblebisatan G., Bay A., Sirikci A., et al. Silent cerebral infarct in child patients with beta thalassaemia intermedia. Blood Coagul Fibrinolysis 2012, 23(7):608-613.
7. Osarogiagbon U.R., Choong S., Belcher J.D., et al. Reperfusion injury pathophysiology in sickle transgenic mice. Blood 2000, 96(1):314-320.
8. Kauf T.L., Coates T.D., Huazhi L., et al. The cost of health care for children and adults with sickle cell disease. Am J Hematol 2009, 84(6):323-327.
9. Hassell K.L. Population estimates of sickle cell disease in the U.S. Am J Prev Med 2010, 38(4 Suppl):S512-S521.
10. Powars D.R., Chan L.S., Hiti A., et al. Outcome of sickle cell anemia: a 4-decade observational study of 1056 patients. Medicine (Baltimore) 2005, 84(6):363-376.
11. Walters M.C., Patience M., Leisenring W., et al. Bone marrow transplantation for sickle cell disease. N Engl J Med 1996, 335(6):369-376.
12. Walters M.C., Patience M., Leisenring W., et al. Barriers to bone marrow transplantation for sickle cell anemia. Biol Blood Marrow Transplant 1996, 2(2):100-104.
13. Giardini C., Angelucci E., Lucarelli G., et al. Bone marrow transplantation for thalassemia. Experience in Pesaro, Italy. Am J Pediatr Hematol Oncol 1994, 16(1):6-10.
14. Bhatia M., Kolva E., Cimini L., et al. Health-related quality of life after allogeneic hematopoietic stem cell transplantation for sickle cell disease. Biol Blood Marrow Transplant 2015, 21(4):666-672.
15. La Nasa G., Caocci G., Efficace F., et al. Long-term health-related quality of life evaluated more than 20 years after hematopoietic stem cell transplantation for thalassemia. Blood 2013, 122(13):2262-2270.
16. Mentzer W.C., Heller S., Pearle P.R., et al. Availability of related donors for bone marrow transplantation in sickle cell anemia. Am J Pediatr Hematol Oncol 1994, 16(1):27-29.
17. Delfini C., Polchi P., Izzi T., et al. Bone marrow donors other than HLA genotypically identical siblings for patients with thalassemia. Exp Hematol 1985, 13(11):1197-1200.
18. Krishnamurti L., Abel S., Maiers M., et al. Availability of unrelated donors for hematopoietic stem cell transplantation for hemoglobinopathies. Bone Marrow Transplant 2003, 31(7):547-550.
19. Justus D., Perez-Albuerne E., Dioguardi J., et al. Allogeneic donor availability for hematopoietic stem cell transplantation in children with sickle cell disease. Pediatr Blood Cancer 2015, 62(7):1285-1287.
20. Kamani N.R., Walters M.C., Carter S., et al. Unrelated donor cord blood transplantation for children with severe sickle cell disease: results of one cohort from the phase II study from the Blood and Marrow Transplant Clinical Trials Network (BMT CTN). Biol Blood Marrow Transplant 2012, 18(8):1265-1272.
21. Lucarelli G., Galimberti M., Polchi P., et al. Bone marrow transplantation in patients with thalassemia. N Engl J Med 1990, 322(7):417-421.
22. Johnson F.L., Look A.T., Gockerman J., et al. Bone-marrow transplantation in a patient with sickle-cell anemia. N Engl J Med 1984, 311(12):780-783.
23. Dedeken L., Le P.Q., Azzi N., et al. Haematopoietic stem cell transplantation for severe sickle cell disease in childhood: a single centre experience of 50 patients. Br J Haematol 2014, 165(3):402-408.
24. Hsieh M.M., Fitzhugh C.D., Tisdale J.F. Allogeneic hematopoietic stem cell transplantation for sickle cell disease: the time is now. Blood 2011, 118(5):1197-1207.
25. Gaziev J., Sodani P., Polchi P., et al. Bone marrow transplantation in adults with thalassemia: Treatment and long-term follow-up. Ann N Y Acad Sci 2005, 1054:196-205.
26. Lucarelli G., Galimberti M., Polchi P., et al. Marrow transplantation in patients with thalassemia responsive to iron chelation therapy. N Engl J Med 1993, 329(12):840-844.
27. McClellan A.C., Luthi J.C., Lynch J.R., et al. High one year mortality in adults with sickle cell disease and end-stage renal disease. Br J Haematol 2012, 159(3):360-367.
28. Ohene-Frempong K., Weiner S.J. Sleeper LA, et al. Cerebrovascular accidents in sickle cell disease: rates and risk factors. Blood 1998, 91(1):288-294.
29. Gladwin M.T., Sachdev V., Jison M.L., et al. Pulmonary hypertension as a risk factor for death in patients with sickle cell disease. N Engl J Med 2004, 350(9):886-895.
30. Angelucci E., Matthes-Martin S., Baronciani D., et al. Hematopoietic stem cell transplantation in thalassemia major and sickle cell disease: indications and management recommendations from an international expert panel. Haematologica 2014, 99(5):811-820.
31. Vermylen C., Cornu G., Ferster A., et al. Haematopoietic stem cell transplantation for sickle cell anaemia: the first 50 patients transplanted in Belgium. Bone Marrow Transplant 1998, 22(1):1-6.
32. Li C., Wu X., Feng X., et al. A novel conditioning regimen improves outcomes in beta-thalassemia major patients using unrelated donor peripheral blood stem cell transplantation. Blood 2012, 120(19):3875-3881.
33. Choudhary D., Sharma S.K., Gupta N., et al. Treosulfan-thiotepa-fludarabine-based conditioning regimen for allogeneic transplantation in patients with thalassemia major: a single-center experience from north India. Biol Blood Marrow Transplant 2013, 19(3):492-495.
34. Bernardo M.E., Piras E., Vacca A., et al. Allogeneic hematopoietic stem cell transplantation in thalassemia major: results of a reduced-toxicity conditioning regimen based on the use of treosulfan. Blood 2012, 120(2):473-476.
35. Bernaudin F., Socie G., Kuentz M., et al. Long-term results of related myeloablative stem-cell transplantation to cure sickle cell disease. Blood 2007, 110(7):2749-2756.
36. Iannone R., Casella J.F., Fuchs E.J., et al. Results of minimally toxic nonmyeloablative transplantation in patients with sickle cell anemia and beta-thalassemia. Biol Blood Marrow Transplant 2003, 9(8):519-528.
37. Horan J.T., Liesveld J.L., Fenton P., et al. Hematopoietic stem cell transplantation for multiply transfused patients with sickle cell disease and thalassemia after low-dose total body irradiation, fludarabine, and rabbit anti-thymocyte globulin. Bone Marrow Transplant 2005, 35(2):171-177.
38. Hussein A.A., Al-Zaben A., Ghatasheh L., et al. Risk adopted allogeneic hematopoietic stem cell transplantation using a reduced intensity regimen for children with thalassemia major. Pediatr Blood Cancer 2013, 60(8):1345-1349.
39. Hsieh M.M., Fitzhugh C.D., Weitzel R.P., et al. Nonmyeloablative HLA-matched sibling allogeneic hematopoietic stem cell transplantation for severe sickle cell phenotype. JAMA 2014, 312(1):48-56.
40. Eapen M., Horowitz M.M., Klein J.P., et al. Higher mortality after allogeneic peripheral-blood transplantation compared with bone marrow in children and adolescents: the Histocompatibility and Alternate Stem Cell Source Working Committee of the International Bone Marrow Transplant Registry. J Clin Oncol 2004, 22(24):4872-4880.
41. Iravani M., Tavakoli E., Babaie M.H., et al. Comparison of peripheral blood stem cell transplant with bone marrow transplant in class 3 thalassemic patients. Exp Clin Transplant 2010, 8(1):66-73.
42. Ghavamzadeh A., Iravani M., Ashouri A., et al. Peripheral blood versus bone marrow as a source of hematopoietic stem cells for allogeneic transplantation in children with class I and II beta thalassemia major. Biol Blood Marrow Transplant 2008, 14(3):301-308.
43. Irfan M., Hashmi K., Adil S., et al. Beta-thalassaemia major: bone marrow versus peripheral blood stem cell transplantation. J Pak Med Assoc 2008, 58(3):107-110.
44. Chu R., Brazauskas R., Kan F., et al. Comparison of outcomes after transplantation of G-CSF-stimulated bone marrow grafts versus bone marrow or peripheral blood grafts from HLA-matched sibling donors for patients with severe aplastic anemia. Biol Blood Marrow Transplant 2011, 17(7):1018-1024.
45. Walters M.C., Patience M., Leisenring W., et al. Stable mixed hematopoietic chimerism after bone marrow transplantation for sickle cell anemia. Biol Blood Marrow Transplant 2001, 7(12):665-673.
46. Imamura M., Tsutsumi Y., Miura Y., et al. Immune reconstitution and tolerance after allogeneic hematopoietic stem cell transplantation. Hematology 2003, 8(1):19-26.
47. Andreani M., Nesci S., Lucarelli G., et al. Long-term survival of ex-thalassemic patients with persistent mixed chimerism after bone marrow transplantation. Bone Marrow Transplant 2000, 25(4):401-404.
48. Panepinto J.A., Walters M.C., Carreras J., et al. Matched-related donor transplantation for sickle cell disease: report from the Center for International Blood and Transplant Research. Br J Haematol 2007, 137(5):479-485.
49. McPherson M.E., Hutcherson D., Olson E., et al. Safety and efficacy of targeted busulfan therapy in children undergoing myeloablative matched sibling donor BMT for sickle cell disease. Bone Marrow Transplant 2011, 46(1):27-33.
50. Kean L.S., Manci E.A., Perry J., et al. Chimerism and cure: hematologic and pathologic correction of murine sickle cell disease. Blood 2003, 102(13):4582-4593.
51. Kang E.M., Areman E.M., David-Ocampo V., et al. Mobilization, collection, and processing of peripheral blood stem cells in individuals with sickle cell trait. Blood 2002, 99(3):850-855.
52. Gragert L., Eapen M., Williams E., et al. HLA match likelihoods for hematopoietic stem-cell grafts in the U.S. registry. N Engl J Med 2014, 371(4):339-348.
53. Luznik L., O'Donnell P.V., Symons H.J., et al. HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biol Blood Marrow Transplant 2008, 14(6):641-650.
54. La Nasa G., Caocci G., Argiolu F., et al. Unrelated donor stem cell transplantation in adult patients with thalassemia. Bone Marrow Transplant 2005, 36(11):971-975.
55. Fleischhauer K., Locatelli F., Zecca M., et al. Graft rejection after unrelated donor hematopoietic stem cell transplantation for thalassemia is associated with nonpermissive HLA-DPB1 disparity in host-versus-graft direction. Blood 2006, 107(7):2984-2992.
56. Kurtzberg J. Update on umbilical cord blood transplantation. Curr Opin Pediatr 2009, 21(1):22-29.
57. Rocha V., Wagner J.E., Sobocinski K.A., et al. Graft-versus-host disease in children who have received a cord-blood or bone marrow transplant from an HLA-identical sibling. Eurocord and International Bone Marrow Transplant Registry Working Committee on Alternative Donor and Stem Cell Sources. N Engl J Med 2000, 342(25):1846-1854.
58. Locatelli F., Kabbara N., Ruggeri A., et al. Outcome of patients with hemoglobinopathies given either cord blood or bone marrow transplantation from an HLA-identical sibling. Blood 2013, 122(6):1072-1078.
59. Adamkiewicz T.V., Szabolcs P., Haight A., et al. Unrelated cord blood transplantation in children with sickle cell disease: review of four-center experience. Pediatr Transplant 2007, 11(6):641-644.
60. Ruggeri A., Eapen M., Scaravadou A., et al. Umbilical cord blood transplantation for children with thalassemia and sickle cell disease. Biol Blood Marrow Transplant 2011, 17(9):1375-1382.
61. McCurdy S.R., Kanakry J.A., Showel M.M., et al. Risk-stratified outcomes of nonmyeloablative HLA-haploidentical BMT with high-dose posttransplantation cyclophosphamide. Blood 2015, 125(19):3024-3031.
62. Kasamon Y.L., Bolanos-Meade J., Prince G.T., et al. Outcomes of nonmyeloablative HLA-haploidentical blood or marrow transplantation with high-dose post-transplantation cyclophosphamide in older adults. J Clin Oncol 2015, 33(28):3152-3161.
63. Bolanos-Meade J., Fuchs E.J., Luznik L., et al. HLA-haploidentical bone marrow transplantation with posttransplant cyclophosphamide expands the donor pool for patients with sickle cell disease. Blood 2012, 120(22):4285-4291.
64. Gaziev D., Polchi P., Lucarelli G., et al. Second marrow transplants for graft failure in patients with thalassemia. Bone Marrow Transplant 1999, 24(12):1299-1306.
65. Gaziev J., Sodani P., Lucarelli G., et al. Second hematopoietic SCT in patients with thalassemia recurrence following rejection of the first graft. Bone Marrow Transplant 2008, 42(6):397-404.
66. Roth M., Krystal J., Manwani D., et al. Stem cell transplant for children with sickle cell anemia: parent and patient interest. Biol Blood Marrow Transplant 2012, 18(11):1709-1715.
67. Mokhtar G.M., Gadallah M., El Sherif N.H., et al. Morbidities and mortality in transfusion-dependent Beta-thalassemia patients (single-center experience). Pediatr Hematol Oncol 2013, 30(2):93-103.
68. Jaing T.H., Hung I.J., Yang C.P., et al. Unrelated cord blood transplantation for thalassaemia: a single-institution experience of 35 patients. Bone Marrow Transplant 2012, 47(1):33-39.
69. Dallas M.H., Triplett B., Shook D.R., et al. Long-term outcome and evaluation of organ function in pediatric patients undergoing haploidentical and matched related hematopoietic cell transplantation for sickle cell disease. Biol Blood Marrow Transplant 2013, 19(5):820-830.
70. Sodani P., Isgro A., Gaziev J., et al. Purified T-depleted, CD34+ peripheral blood and bone marrow cell transplantation from haploidentical mother to child with thalassemia. Blood 2010, 115(6):1296-1302.